Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma;Uaktualnione zalecenia dotycza̧ce systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego miȩdzybłoniaka opłucnej

Nowotwory

Volumn 60, Issue 3, 2010, Pages 258-270

  Jassem, Jacek ^a   Biernat, Wojciech ^a   Drosik, Kazimierz ^b   Dziadziuszko, Rafał ^a   Kordek, Radzisław ^c   Kozielski, Jerzy ^d   Kowalski, Dariusz M ^e   Krzakowski, Maciej ^e   Nikliński, Jacek ^f   Olszewski, Włodzimierz ^e   Orłowski, Tadeusz ^g   Ramlau, Rodryg ^h   Roszkowski Śliz, Kazimierz ^g   Rzyman, Witold ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Wojewódzki Ośrodek Onkologiczny ^*  (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f Samodzielny Publiczny Dzieci cy Szpital Kliniczny   (Poland)

^g INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

^h GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; REVIEW; SYSTEMIC THERAPY;

EID: 79551627479     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Didkowska J, Wojciechowska U, Tarkowski W i wsp. Nowotwory złośliwe w Polsce w 2006 roku. Warszawa: Centrum Onkologii - Instytut, 2008.
2. Bülzebruck H, Bopp R, Drings P i wsp. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-10.
3. Naruke T, Goya T, Tsuchiya R i wsp. Prognosis and survival in resected lung carcinoma based on the international staging system. J Thorac Cardiovasc Surg 1998; 96: 440-7.
4. Jassem J, Skokowski J, Dziadziuszko R i wsp. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 2000; 119: 1141-6. (Pubitemid 30412610)
5. Jassem J, Drosik K, Dziadziuszko R i wsp. Zalecenia dotycza̧ce systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego miȩdzybłoniaka opłucnej: Konferencja okra̧głego stołu. Nowotwory J Oncol 2005; 55: 160-6.
6. Jassem J, Drosik K, Dziadziuszko R i wsp. Systemowe leczenie niedrobnokomórkowego raka płuca i złośliwego miȩdzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Nowotwory J Oncol, 2007; 57: 71-8.
7. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 2004.
8. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-68.
9. Scagliotti GV, Parikh P, von Pawel J i wsp. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
10. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J Clin Oncol 2007; 25: 587-95. (Pubitemid 350002967)
11. Johnson DH, Fehrenbacher L, Novotny WF i wsp. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91. (Pubitemid 41095154)
12. Barlesi F, Pinot D, Legoffic A i wsp. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 2005; 93: 450-2. (Pubitemid 43080019)
13. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo BF. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 2006; 37: 542-6.
14. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004; 8: 259-67. (Pubitemid 39370567)
15. Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 2006; 19: 1117-23. (Pubitemid 44106727)
16. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-20. (Pubitemid 350307847)
17. Khayyata S, Yun S, Pasha T i wsp. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009; 37: 178-83.
18. Sturm N, Lantuejoul S, Laverriere MH i wsp. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001; 32: 918-25. (Pubitemid 32911313)
19. Tan D, Li Q, Deeb G i wsp. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol 2003; 34: 597-604. (Pubitemid 36750372)
20. Nicholson AG, Gonzalez D, Shah P i wsp. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010 (w druku).
21. Aida S, Shimazaki H, Sato K i wsp. Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types. Histopathology 2004; 45: 468-76. (Pubitemid 39524321)
22. Yokose T, Suzuki K, Nagai K i wsp. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 2000; 29: 179-88.
23. Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (supl. 4): 73-5.
24. Butnor KJ, Sporn TA, Ordonez NG. Recommendations for the reporting of pleural mesothelioma. Virchows Arch 2007; 450: 15-23.
25. Churg A, Colby TV, Cagle P i wsp. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24: 1183-200.
26. Rosell R, Gomez-Codina J, Camps C i wsp. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8. (Pubitemid 24026882)
27. Roth JA, Fosella F, Komaki R i wsp. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80.
28. Depierre A, Milleron B, Moro-Sibilot D i wsp. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-53. (Pubitemid 34032618)
29. Gilligan D, Nicolson M, Smith I i wsp. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-37. (Pubitemid 46874559)
30. Pisters K, Vallieres E, Bunn PA Jr i wsp. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. J Clin Oncol 2007; 25 (supl): 389s (abstrakt).
31. Scagliotti GV, Pastorino U, Vansteenkiste JF i wsp. A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): follow-up data on Ch.E.S.T. J Clin Oncol 2008; 26 (supl): 399 (abstrakt).
32. Burnett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006; 1: 611-21. (Pubitemid 47163946)
33. Felip E, Massuti B, Alonso G i wsp. Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): results of the NATCH. J Clin Oncol 2009; 27 (supl): 382s (abstrakt).
34. Lim E, Harris G, Patel A i wsp. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison of randomized trials. J Clin Oncol 2008; 26 (supl): 408 (abstrakt).
35. van Meerbeeck JP, Kramer GW, Van Schil PE i wsp. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-50. (Pubitemid 47073567)
36. Albain KS, Swann RS, Rusch VW i wsp. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-86.
37. Rusch VW, Giroux DJ, Kraut MJ i wsp. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25: 313-8. (Pubitemid 350003020)
38. Kunitoh H, Kato H, Tsuboi M i wsp. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol 2008; 26: 644-9. (Pubitemid 351264361)
39. Kappers I, van Sandick JW, Burgers JA i wsp. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 2009; 36: 741-6.
40. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br Med J 1995; 311: 899-909.
41. Keller SM, Adak S, Wagner H i wsp. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000; 343: 1217-22.
42. Waller D, Peake MD, Stephens RJ i wsp. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26: 173-82. (Pubitemid 38759943)
43. Scagliotti GV, Fossati R, Torri V i wsp. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003; 95: 1453-61.
44. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-60.
45. Winton T, Livingston R, Johnson D i wsp. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97. (Pubitemid 41007845)
46. Strauss GM, Herndon II JE, Maddaus MA i wsp. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006; 24 (supl): 365s (abstrakt).
47. Kato H, Ichinose Y, Ohta M i wsp. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21. (Pubitemid 38501140)
48. Douillard J-Y, Rosell R, De Lena M i wsp. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27. (Pubitemid 44283661)
49. Pignon JP, Tribodet H, Scagliotti GV i wsp. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
50. Burdett S, Arriagada R, Lesley S i wsp. Chemotherapy (CT) in addition to surgery or surgery plus radiotherapy (RT) in non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomized controlled trials (RCTs) J Thorac Oncol 2007; 2 (supl): 366.
51. Butts CA, Ding K, Seymour L i wsp. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29-34.
52. Hotta K, Matsuo K, Ueoka H i wsp. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3860-7. (Pubitemid 41079866)
53. Alam N, Shepherd FA, Winton T i wsp. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and Intergroup Trial JBR.10 and a review of the literature. Lung Cancer 2005; 47: 385-94. (Pubitemid 40248743)
54. Arriagada R, Dunant A, Pignon J-P i wsp. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28: 35-42.
55. Wrona A, Jassem J. Nowa klasyfikacja TNM w raku płuca. Onkol Prakt Klin 2010 (w druku).
56. Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lancet Oncol 2001; 2: 335-42. (Pubitemid 33585938)
57. Rolland E, Le Chevalier T, Auperin A i wsp. Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-anayles using individual patent data (IPD) from randomised clinical Trials (RCTs). J Thorac Oncol 2007; 2 (supl): 309.
58. Auperin A, Estelle R, Walter C i wsp. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patent data (IPD) from randomised clinical trials. J Thorac Oncol 2007; 2 (supl): 310.
59. Rowell NP, O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 2: CD002140.
60. De Ruysscher D, Botterweck A, Dirx M i wsp. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102.
61. Machtay M, Hsu C, Komaki R i wsp. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small- cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005; 63: 667-71. (Pubitemid 41400050)
62. Vokes EE, Herndon JE, Kelley MJ i wsp. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-704. (Pubitemid 46797950)
63. Hanna NH, Neubauer M, Yiannoutso C i wsp. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-60.
64. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-25.
65. Baggstrom MQ, Stinchcombe TE, Fried DB i wsp. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007; 2: 845-53. (Pubitemid 47361027)
66. Goffin J, Lacchetti Ch, Ellis PM i wsp. First line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. J Thorac Oncol 2010; 5 (2): 260-74.
67. Delbaldo C, Michelis S, Syz N i wsp. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-84. (Pubitemid 38988956)
68. Alberola V, Camps C, Provencio M i wsp. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-13. (Pubitemid 46606251)
69. Hatem AA, Elttar I, Loberizo Jr FR i wsp. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer 2009; 64: 194-8.
70. Ardizzoni A, Boni L, Tiseo M i wsp. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-57.
71. Kelly K, Crowley J, Bunn PA Jr i wsp. Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-8. (Pubitemid 32591438)
72. Schiller JH, Harrington D, Belani CP i wsp. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-8. (Pubitemid 34438899)
73. Greco AF, Gray, JR, Thompson DS i wsp. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma. Cancer 2002; 95: 1279-85.
74. Gao G, Jiang J, Liang X i wsp. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009; 65: 339-344.
75. Gronberg BH, Bremnes RM, Flotten O i wsp. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 3217-23.
76. Le Chevalier T, Scagliotti G, Natale R i wsp. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47: 69-80. (Pubitemid 39643243)
77. Douillard JY, Laporte S, Fossella F i wsp. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007; 2: 939-46. (Pubitemid 47511598)
78. Park JO, Kim SW, Ahn JS i wsp. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5233-9.
79. von Plessen C, Bergman B, Andresen O i wsp. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95: 966-73. (Pubitemid 44606820)
80. Socinski MA, Schell MJ, Peterman A i wsp. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002; 20: 1335-43. (Pubitemid 34182817)
81. Smith IE, O'Brien MER, Talbot DC i wsp. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three vs six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19: 1336-43. (Pubitemid 32202538)
82. Brodowicz T, Krzakowski M, Zwitter M i wsp. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.
83. Soon YY, Stockler MR, Askie LM i wsp. Duration of chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis of randomized trials. J Clin Oncol 2009; 20: 3277-84.
84. da Silveira JP, dos Santos LV, Sasse E Ch i wsp. Optimal duration of first-line chemotherapy for advanced non-small-cell lung cancer: A systematic review with meta-analysis. Eur J Cancer 2009; 45: 601-607.
85. Fidias P, Dakhil SR, Lyss AP i wsp. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. J Clin Oncol 2009; 27: 591-8.
86. Ciuleanu T, Brodowicz T, Zielinski C i wsp. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-40.
87. Gatzemeier U, von Pavel J, Gottfried M. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 3390-9.
88. Langer CJ, Manola J, Bernardo P i wsp. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-81. (Pubitemid 34162751)
89. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91: 66-72.
90. Frasci G, Lorusso V, Panza N i wsp. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18: 2529-36. (Pubitemid 30432518)
91. Hainsworth JD, Spigel DR, Farley C i wsp. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110: 2027-34. (Pubitemid 350036863)
92. Lilenbaum RC, Herndon JE 2nd, List MA i wsp. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-6. (Pubitemid 41702638)
93. Barlesi F, Jacot W, Astoul P, Pujol J-L. Second-line treatment for advanced non-small-cell lung cancer: a systematic review. Lung Cancer 2006; 51: 159-172. (Pubitemid 43144359)
94. Di Maio M, Chiodini P, Georgoulias V i wsp. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as a second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 1836-43.
95. Shepherd FA, Dancey J, Ramlau R i wsp. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103. (Pubitemid 30324363)
96. Fossella FV, DeVore R, Kerr RN i wsp. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-62. (Pubitemid 30415821)
97. Hanna N, Shepherd FA, Fossella FV i wsp. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97. (Pubitemid 41079796)
98. Tassinari D, Scarpi E, Sartori S i wsp. Second line treatments in non-small- cell lung cancer: A review of literature and metaanalysis of randomized clinical trials. Chest 2009; 135: 1596-609.
99. Di Maio M, Lama N, Morbiato A i wsp. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. Eur J Cancer 2010; 46: 735-43.
100. Herbst RS, Prager D, Hermann R i wsp. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892-9.
101. Gatzemeier U, Pluzanska A, Szczesna A i wsp. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52. (Pubitemid 46733081)
102. Giaccone G, Herbst RS, Manegold C i wsp. Gefitynib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-84. (Pubitemid 41103588)
103. Herbst RS, Giaccone G, Schiller JH i wsp. Gefitynib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-94. (Pubitemid 41103589)
104. Mok TS, Wu YL, Thongprasert S i wsp. Gefitynib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
105. Shepherd FA, Pereira RJ, Ciuleanu T i wsp. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
106. Bezjak A, Lee CW, Ding K i wsp. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008; 26: 5052-9.
107. Zhu CQ, da Cunha Santos G, Ding K i wsp. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-75.
108. Bradbury PA, Tu D, Seymour L i wsp. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010; 102: 1-9.
109. Thatcher N, Chang A, Parikh P i wsp. Gefitynib plus best supportive care in previously treated patients with refractory advanced non-small- cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37. (Pubitemid 41540110)
110. Kim ES, Hirsch V, Mok T i wsp. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-18.
111. Douillard J-Y, Shepherd FA, Hirsch V i wsp. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28: 744-52.
112. Cappuzzo F, Ciuleanu T, Stelmakh L i wsp. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. Lancet Oncol 2010 (w druku).
113. Takeda K, Hida T, Sato T i wsp. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Trial (WJTOG-0203). J Clin Oncol 2010; 28: 753-60.
114. Miller VA, O'Connor P, Soh C i wsp. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (supl): 18s (abstrakt).
115. Pirker R, Pereira JR, Szczesna A i wsp. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31.
116. Lynch TJ, Patel T, Dreisbach Li wsp. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-7.
117. O'Byrne KJ, Bondarenko I, Barrios C i wsp. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol 2009; 27 (supl): 15s (abstrakt).
118. Sandler A, Gray R, Perry MC i wsp. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50. (Pubitemid 44917502)
119. Sandler AB, Kong G, Strickland D i wsp. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3 Suppl. 4: S283.
120. Reck M, von Pawel J, Zatloukal P i wsp. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27: 1227-34.
121. Sanjaykumar H, Chu D, Shenhong W. Risk of gastrointestinal perforation in patients with cancer treaded with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10: 559-68.
122. Nalluri SR, Chu D, Keresztes R i wsp. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizunab in cancer patients. JAMA 2008; 300:2277-85.
123. Muers MF, Stephens RJ, Fisher P i wsp. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94. (Pubitemid 351671885)
124. Vogelzang NJ, Rusthoven JJ, Symanowski J i wsp. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44. (Pubitemid 46606305)
125. Symanowski J, Rushoven J, Nguyen B i wsp. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin in malignant pleural mesothelioma (abstrakt). Proc Am Soc Clin Oncol 2003; 22: 647.
126. Jassem J, Ramlau R, Santoro A i wsp. Pemetrexed plus best supportive care versus best supportive care in previously treated patients with advanced malignant pleural mesothelioma: A randomized phase III trial. J Clin Oncol 2008; 26: 1698-704.
127. Weder W, Stahel RA, Bernhard J i wsp. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-202. (Pubitemid 47244366)
128. De Perrot M, Feld R, Cho B i wsp. Trimodality therapy with induction chemotherapy followed bu extrapleural pneumonectomy and adjuvant high -dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-8.
129. Krug L, Pass H, Rusch V i wsp: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-13.
130. Bokulbas S, Manegold C, Eberlein M i wsp. Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2010 (w druku).